Table 1.
Demographic characteristics of the 44 patients with Crohn’s disease.
| Total (N = 44) | Continuous treatment group (n = 32) | Additional treatment group (n = 12) | P* | |
|---|---|---|---|---|
| Age at the start of treatment with mesalazine granule formulation (years) | 39.9 ± 13.0 | 41.0 ± 14.8 | 37.0 ± 5.6 | 0.37 |
| Sex (male/female) | 29/15 | 20/12 | 9/3 | 0.44 |
| Age at diagnosis (years) | 27.0 ± 11.6 | 27.6 ± 13.1 | 25.3 ± 6.5 | 0.56 |
| Disease duration (years) | 12.9 ± 9.1 | 13.4 ± 9.6 | 11.8 ± 8.2 | 0.61 |
| Duration of tablet use (years) | 11.7 ± 7.4 | 11.8 ± 7.4 | 11.3 ± 7.7 | 0.84 |
| Smoking history | ||||
| Current/past/never | 8/10/26 | 4/8/20 | 4/2/6 | 0.28 |
| Anal lesions (%) | 20 (45.5) | 10 (31.3) | 10 (83.3) | 0.002 |
| Surgical history | 25 (56.8) | 18 (56.3) | 7 (58.3) | 0.9 |
| Concomitant drug | ||||
| Immunomodulator | 18 (40.9) | 14 (43.8) | 4 (33.3) | 0.53 |
| Steroid | 2 (4.5) | 1 (3.1) | 1 (8.3) | 0.46 |
| Anti-TNF | 20 (45.5) | 16 (50.0) | 4 (33.3) | 0.32 |
| Elemental diet | 26 (59.1) | 16 (50.0) | 10 (83.3) | 0.045 |
| Montreal classification | ||||
| A1/A2/A3 | 4/36/4 | 4/24/4 | 0/12/0 | 0.16 |
| L1/L2/L3 | 13/4/27 | 10/2/20 | 3/2/7 | 0.55 |
| B1/B2/B3 | 14/17/13 | 11/10/11 | 3/7/2 | 0.24 |
| CDAI | 105.5 ± 90.8 | 101.7 ± 86.9 | 115.8 ± 101.3 | 0.65 |
| Serum CRP (mg/dl) | 0.34 ± 0.49 | 0.36 ± 0.52 | 0.27 ± 0.40 | 0.61 |
| Alb (g/dl) | 4.2 ± 0.5 | 4.1 ± 0.5 | 4.4 ± 0.4 | 0.04 |
| Hb (g/dl) | 13.1 ± 1.5 | 12.9 ± 1.5 | 13.8 ± 1.5 | 0.09 |
| Compliance rate (%) | 81.0 ± 23.2 | 80.5 ± 22.0 | 79.1 ± 19.2 | 0.81 |
TNF tumor necrosis factor, CDAI Crohn’s Disease Activity Index, CRP C-reactive protein, Alb albumin, Hb hemoglobin.
*Continuous treatment group vs. additional treatment group.